R&D update: Dong-A seeks to expand udenafil's uses with new indications
This article was originally published in Scrip
Udenafil, a phosphodiesterase-5 (PDE-5) inhibitor developed by South Korea's Dong-A Pharmaceutical, is moving forward in a number of new indications on top of its main commercial use for erectile dysfunction (ED).
You may also be interested in...
A busy stretch of deal-making across Asia all includes transactions involving Innovent, Alector, Ono, Numab, Alphamab, 3DMed, Healios, Athersys, Laekna, Novartis, Asahi Kasei, SBI Biotech, Glenmark, Hindustan Unilever, Hanlim, Alteogen, Ildong, Evotec, AJU Pharm, Ribomec, Tyligand, Context
New potential topical therapy in dermatitis space set to move towards Japan approval submission based on positive new results.
Japan approval for BTK inhibitor marks new indication but in a small niche market, while another clearance may help extend Latuda's commercial life.